Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ)
- Previous Close
9.19 - Open
9.02 - Bid 9.20 x --
- Ask 9.22 x --
- Day's Range
9.01 - 9.22 - 52 Week Range
6.89 - 12.97 - Volume
5,152,012 - Avg. Volume
6,213,274 - Market Cap (intraday)
12.145B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
-- - EPS (TTM)
-0.53 - Earnings Date Apr 29, 2024
- Forward Dividend & Yield 0.10 (1.08%)
- Ex-Dividend Date Jul 18, 2023
- 1y Target Est
6.40
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, production, and sell of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
www.hepalink.com2,080
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 002399.SZ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002399.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002399.SZ
Valuation Measures
Market Cap
12.14B
Enterprise Value
15.44B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.48
Price/Book (mrq)
1.14
Enterprise Value/Revenue
2.84
Enterprise Value/EBITDA
-46.58
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.38%
Return on Assets (ttm)
-0.74%
Return on Equity (ttm)
-6.58%
Revenue (ttm)
5.45B
Net Income Avi to Common (ttm)
-783.26M
Diluted EPS (ttm)
-0.53
Balance Sheet and Cash Flow
Total Cash (mrq)
2.27B
Total Debt/Equity (mrq)
46.40%
Levered Free Cash Flow (ttm)
57.09M
Research Analysis: 002399.SZ
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 002399.SZ
002399.SZ does not have Company Insights